DUBLIN, May 20- Royalty Pharma raised its hostile bid for Elan to $12.50 per share and heaped pressure on shareholders, saying it will withdraw the bid if they approve a series of defensive transactions announced by the Irish drug firm.
Global deal-making fell in June but more tech and retail names are in the pipeline and ripe for acquisitions , with Marshall Sonenshine, Sonenshine Partners chairman/CEO.
A look at M&A activity and where to find investment opportunities, with Joseph Perella, Perella Weinberg Partners CEO; Terry Meguid, Perella Weinberg Partners; and Peter Weinberg, Perella Weinberg Partners.
The online video service may put itself on the auction block after receiving an unsolicited takeover bid. A look at potential buyers, with CNBC's Julia Boorstin.
Weighing in on International Paper's hostile takeover bid of Temple-Inland for $30.60/share, and the outlook on the markets, with Keith McCullough, Hedgeye Risk Management; Robert Froehlich, The Hartford, and CNBC's Brian Sullivan.